Letrozole clinical trials

Explore recruiting letrozole clinical trials.

Recruiting letrozole studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Letrozole trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial

Italy, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA -Mutated, Hormone Receptor-Positive, HER2- Negative Advanced Breast Cancer

Germany, Italy, France, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4391025_AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Italy, Spain, France, Slovakia, Germany, Sweden +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer

Belgium, France, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Clinical and endocrinological effects of letrozole during the luteal phase after controlled ovarian stimulation in oocyte donors: a low interventional, randomized, controlled trial

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Letrozole trials by city

Letrozole in Toronto Letrozole in Vancouver Letrozole in Montreal Letrozole in Calgary Letrozole in Edmonton Letrozole in Ottawa Letrozole in Winnipeg Letrozole in Quebec City Letrozole in Hamilton Letrozole in Kitchener Letrozole in London Letrozole in Halifax Letrozole in New York Letrozole in Los Angeles Letrozole in Chicago Letrozole in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease